The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

- Cortical Excitability in Amyotrophic Lateral Sclerosis 11
- Epidemiology of Multiple Sclerosis 17
- Hemodilution in Brain Ischemia 30
- Lewy Bodies in Trisomy 21 48
- Complete Table of Contents i

XXVIIIth Canadian Congress of Neurological Sciences
June 16-19, 1993
Toronto, Ontario

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association for Child Neurology

Volume 20, No. 1 **February 1993**

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

The Canadian Journal of Neurological Sciences

VOLUME 20, NO. 1, FEBRUARY, 1993

Le Journal Canadien des Sciences Neurologiques

Table of Contents

ARTICLES

Message from the Editor 1

List of 1992 Reviewers 2

A Quarter Century's Experience with Intraoperative Nerve Action Potential Recording
David G. Kline and Leo T. Happel 3

Cortical Excitability in Amyotrophic Lateral Sclerosis: A Clue to Pathogenesis
Andrew Eisen, Bhanu Pant and Heather Stewart 11

Epidemiology of Multiple Sclerosis: A Critical Overview
A.D. Sadovnick and G.C. Ebers 17

Focal Cerebral Ischemia in Rats: Effect of Hemodilution with α-α Cross-Linked Hemoglobin on Brain Injury and Edema
Daniel J. Cole, Randall M. Schell, John C. Drummond, Robert J. Pryzbelski and Suzzane Marcantonio 30

Acidic Fibroblast Growth Factor Infusion Reduces Ischemic CA1 Hippocampal Damage in the Gerbil
V. MacMillan, K. Walton-Roche and J. Davis 37

Failure of Iron Chelators to Protect Against Cerebral Infarction in Hypoxia-Ischemia
V. MacMillan, I. Fridovich and J. Davis 41

Single-Blind Study of Dystrophin Staining in Carriers of Duchenne Muscular Dystrophy
Francois P. Bernier, Cheryl R. Greenberg, William C. Halliday and Klaus Wrogemann 44

Detection of Lewy Bodies in Trisomy 21 (Down's Syndrome)
Ravi Raghavan, Clare Khin-Nu, Andrew Brown, Dorothy Irving, Paul G. Ince, Kenneth Day, Stephen P. Tyrer and Robert H. Perry 48

A Double-Blind Cross-over Trail of Amantadine Hydrochloride in Friedreich's Ataxia
A. Filla, G. De Michele, G. Orefice, F. Santorelli, L. Trombetta, S. Banfi, F. Squitieri, G. Napolitano, D. Puma and G. Campanella 52

Anterior Interosseous Neuropathy in the Postpartum Period
Lionel Carmant and Martin Veilleux 56

Cervical Disc Herniation Presenting with Chest Wall Pain
Michael C. Yeung and Neil A. Hagen 59

Horner's Syndrome Secondary to Angiogram Negative, Subadventitial Carotid Artery Dissection
M. Assaf, P.J. Sweeney, G. Kosmorsky and T. Masaryk 62

Supratentorial Glioblastoma with Spinal Cord Intramedullary Metastasis
Mark G. Hamilton, Bruce I. Tranmer and Neil A. Hagen 65

HYPOTHESIS

Epineurial Peptides: A Role in Neuropathic Pain?
D.W. Zochodne 69

ABSTRACTS

Abstracts of the 32nd Annual Meeting of the Canadian Association of Neuropathologists, September 1992, Toronto, Ontario 73

NOTES AND ANNOUNCEMENTS 90

CALENDAR OF EVENTS 91

BOOKS RECEIVED 92

BOOK REVIEWS 92

ADVERTISERS INDEX xxv

INSTRUCTIONS TO AUTHORS xxvi

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

The permanent secretariat for the 4 societies and the Canadian Congress of Neurological Sciences is at/
Le secrétariat des 4 associations et du Congrès Canadien des Sciences Neurologiques est situe en permanence à:
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is $60 for members; $70 for non-members in Canada; $80 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students $30 per annum (members); $40 per annum (non-members). Single copies $18 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575.
 Mailed under Publications Mail registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus, Excerpta Medica and Current Contents — Clinical Practice and Life Sciences.*

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 60 $ pour les membres; 70 $ pour les non-membres au Canada; 80 $ pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 30 $ par année (membres); 40 $ par année (non-membres). Copie simple: 18 $ plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Par courrier: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575.
 Posté sous permis de poste-publications no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus, Excerpta Medica et Current Contents — Clinical Practice et Life Sciences.*

Advertising representative/Représentant de publicité Sally Gregg, Canadian Journal of Neurological Sciences
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7 — (403)-229-9575

Printer/Imprimeur McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

There's only one thing your TIA patients want from a stroke prevention therapy.

Tomorrow.

What patients at risk want most is the reassurance everything possible is being done to prevent another event.

By making Ticlid a part of your patients' treatment, you can give them that reassurance.

Because for non-cardiogenic thromboembolic stroke – the most common form of the disease[1] – there is no therapy proven more effective than Ticlid.

In two landmark studies, Ticlid has been shown to significantly reduce the risk of both initial and recurrent stroke.[2,3]

During the critical first year after a TIA, Ticlid reduced the incidence of stroke by nearly half relative to ASA. And its superiority was maintained over a 5 year term, in women as well as men.[2,4]

Ticlid also performed significantly better than placebo in recurrent stroke, and remains the only therapy indicated for the prevention of initial and recurrent stroke in both men and women.[3,5]

With Ticlid, side effects have been shown to be manageable, transient and to occur early in therapy, with most common side effects being relieved by a temporary dose reduction.[2,6]

In clinical trials, there was a 2.4% incidence of neutropenia (0.8% severe). Upon immediate discontinuation of therapy, the neutrophil count usually returned to normal within one to three weeks.[2,3]

To manage the condition requires regular WBC monitoring every two weeks for the first three months of therapy.[6]

Ticlid. After you tell your patients about the risk of stroke, tell them about Ticlid.

And let them get on with their lives.

Ticlid Information Hotline
1-800-263-8918
Dosage: 250 mg BID with meals

Ticlid®

ticlopidine hydrochloride 250 mg tablets

Nothing protects patients from stroke more effectively.

SYNTEX® PAAB CCPP

For brief prescribing information see page vi

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

Ticlid®

TICLID (ticlopidine hydrochloride) 250 mg Tablets
THERAPEUTIC CLASSIFICATION Inhibitor of Platelet Function
ACTION Ticlid (ticlopidine hydrochloride) is an inhibitor of platelet aggregation. It causes a time and dose-dependent inhibition of platelet aggregation and release of platelet factors, as well as a prolongation of bleeding time. The drug has no significant in-vitro activity.
The exact mechanism of action is not fully characterized, but does not involve inhibition of the prostacyclin/thromboxane pathways or platelet cAMP.
Ticlid interferes with platelet membrane function by inhibiting ADP-induced platelet-fibrinogen binding and subsequent platelet-platelet interactions. The effect of Ticlid on platelet function is irreversible.
Template bleeding time is usually prolonged by two to five-fold of baseline values with the therapeutic dose of Ticlid.
Upon discontinuation of Ticlid dosing, bleeding time and other platelet function tests return to normal within one week in the majority of patients.
The correlation between ticlopidine hydrochloride plasma levels and activity is still under investigation. Much of the following data was obtained from older patients corresponding to the age of patients participating in clinical trials (mean age: 63 years).
After oral administration of the therapeutic dose of Ticlid, rapid absorption occurs, with peak plasma levels occurring at approximately 2 hours after dosing. Absorption is at least 80% complete. Administration of Ticlid after meals results in an increased (20%) level of ticlopidine hydrochloride in plasma.
Steady state plasma levels of ticlopidine hydrochloride in plasma are obtained after approximately 14 days of dosing at 250 mg BID. The terminal elimination half-life is 4-5 days. However, inhibition of platelet aggregation is not correlated with plasma drug levels.
Ticlopidine hydrochloride binds reversibly (98%) to plasma proteins, mainly to serum albumin and lipoproteins in a non-saturable manner.
Ticlopidine hydrochloride is metabolized extensively by the liver; no intact ticlopidine hydrochloride is detected in the urine. Unmetabolized ticlopidine hydrochloride is a minor component in plasma after a single dose, but at steady state, ticlopidine hydrochloride is the major component.
Impaired hepatic function resulted in higher than normal plasma levels of unchanged ticlopidine hydrochloride after single doses or after multiple doses.
Inhibition of platelet aggregation is detected within 2 days of administration with 250 mg BID. Maximum platelet aggregation inhibition is achieved 8 to 11 days following dosing with 250 mg BID.
INDICATIONS AND CLINICAL USE Ticlid (ticlopidine hydrochloride) tablets are indicated for reduction of the risk of first or recurrent stroke for patients who have experienced at least one of the following events: Complete Thromboembolic Stroke, Minor Stroke, Reversible Ischemic Neurological Deficit (RIND), or Transient Ischemic Attack (TIA) including Transient Monocular Blindness (TMB).
CONTRAINDICATIONS Ticlid (ticlopidine hydrochloride) is contraindicated in the following conditions: 1. Known hypersensitivity to drug or its excipients. 2. Presence of haematopoietic disorders (such as neutropenia and/or thrombocytopenia). 3. Presence of haemostatic disorder. 4. Conditions associated with active bleeding, such as bleeding peptic ulcer or intracranial bleeding. 5. Severe liver dysfunction.
WARNINGS The following warnings were developed from clinical trial experience with over 2000 patients with cerebrovascular disease who were treated with ticlopidine for as long as 5.8 years.
Neutropenia and Thrombocytopenia: About 2.4% of ticlopidine-treated patients in clinical trials developed neutropenia (defined as an absolute neutrophil count (ANC) below 1.2×10^9 cells/L). The incidence of severe neutropenia (ANC<0.45×10^9 cells/L) was 0.8%. Severe neutropenia occurs during the first 3-12 weeks of therapy, and may develop quickly over a few days. The bone marrow shows a reduction in myeloid precursors. The condition is reversible, and recovery usually occurs within 1-3 weeks after discontinuation of the drug.
In clinical trials, thrombocytopenia (defined as a platelet count of <0.8×10^{11} cells/L) has been observed in 0.4% of ticlopidine patients. The incidence of thrombocytopenia in patients on ASA or placebo was 0.3% or 0.4% respectively. The thrombocytopenia may occur as an isolated finding or in combination with neutropenia. Thrombocytopenia occurs during the first 3-12 weeks of therapy, and recovery usually occurs after drug discontinuation.
All patients should have a white blood cell count with a differential count and platelet count performed every 2 weeks during the first 3 months of therapy. The incidence of neutropenia or thrombocytopenia after three months of therapy is not appreciably higher than the background levels observed in control groups, and continued periodic monitoring is not warranted. However, for the duration of ticlopidine therapy, any signs or symptoms suggestive of neutropenia or thrombocytopenia should be promptly investigated with complete blood counts and platelet counts.
Hemorrhagic Complications: Prolongation of bleeding time occurs in subjects treated with Ticlid. Purpura and a few cases of more serious hemorrhagic events such as hematemesis, melena, hemothorax and intracranial bleeding have been reported. Patients must be instructed to watch for signs of bleeding disorders and to report any abnormality to their physician immediately. Ticlid therapy has to be stopped by the patient if a physician is not immediately available for consultation.
Anticoagulant Drugs: Should be avoided as tolerance and safety of simultaneous administration with Ticlid has not been established.
Hepatic Abnormalities: Most patients receiving ticlopidine hydrochloride showed some increase of their alkaline phosphatase values above their baseline and in one-third the increase exceeded the upper reference range. In 6% the value was greater than twice the upper reference range. These increases in alkaline phosphatase were nonprogressive and asymptomatic. In clinical trials, two cases (0.1%) of cholestatic jaundice accompanied by elevated transaminases alkaline phosphatase, and bilirubin levels above 43µmol/L have been observed. Both patients recovered promptly upon drug discontinuation.
Pregnancy: The safety of Ticlid in pregnancy has not been established. It should not be used in pregnant patients.
Pediatric Use: Safety in children has not been studied. Do not use in pediatric patients.
PRECAUTIONS
Clinical Monitoring: All patients have to be carefully monitored for clinical signs and symptoms of adverse drug reactions (see ADVERSE REACTIONS). The signs and symptoms possibly related to neutropenia (fever, chills, sore throat, ulcerations in oral cavity), thrombocytopenia and abnormal hemostasis (prolonged or unusual bleeding, bruising, purpura, dark stool), jaundice (including dark urine, light coloured stool) and allergic reactions should be explained to the patients who should be advised to stop medication and consult their physician immediately if any of these occur.
Laboratory Monitoring: All patients should have a WBC count with differential and platelet count performed every 2 weeks during the first 3 months of therapy. Thereafter, the WBC counts need only be repeated for symptoms or signs suggestive of neutropenia. Liver function tests should be conducted during therapy with Ticlid (ticlopidine hydrochloride) in response to signs and symptoms suggestive of hepatic dysfunction.
Elective Surgery: Ticlid should be discontinued 10 to 14 days prior to elective surgery or dental extraction and bleeding time and thrombocyte count performed before the procedure if clinically indicated.
Emergency Surgery: Prolonged bleeding during surgery may be a problem in ticlopidine-treated patients. Transfusions of fresh platelets would be expected to improve haemostasis in such patients, but there are no data from clinical trials to confirm this expectation. There are data from clinical pharmacology trials that indicate treatment with glucocorticosteroids can normalize bleeding time in ticlopidine treated subjects, but there is no experience with ticlopidine-treated surgical patients to show that such treatment improves haemostasis.
Selection of Patients: Ticlid should be used only for the established indications (see INDICATIONS) and should not be given to patients with haematopoietic disorders, haemostatic disorders, patients suffering from conditions associated with active bleeding (see CONTRAINDICATIONS) and patients anticipating elective surgery. In clinical trials elderly patients tolerated the drug well, but safety in children and pregnant women has not been established.
Specific Precautions: Liver: Ticlid is contraindicated in patients with severe liver dysfunction or cholestatic jaundice. Mild increase of Alkaline Phosphatase may be seen for the duration of the treatment and is inconsequential in the majority of patients (see WARNINGS and CONTRAINDICATIONS).
Kidneys: Ticlid has been well tolerated in patients with moderately decreased renal function. In severe renal disease, caution and close monitoring are recommended.
Gastrointestinal System: Conditions associated with active bleeding, such as bleeding ulcers, constitute contraindication for Ticlid. Clinical judgement and monitoring of stool for occult blood are required for patients with a history of ulcerative lesions. Trauma: Ticlid should be discontinued temporarily until the danger of abnormal bleeding is eliminated. A single fatal case of intracranial bleeding following head trauma has been reported. The extent to which Ticlid may have contributed to the severity of the bleeding is unknown.
Drug Interactions: The following table outlines the agents which have been concomitantly administered with ticlopidine hydrochloride and the observed interaction if any:

AGENTS	OBSERVED INTERACTION
Acetylsalicylic acid (ASA)	Potentiation of ASA's effect on collagen-induced platelet aggregation (see WARNINGS).
Antipyrine and products metabolized by hepatic microsomal enzymes	30% increase in t1/2 of antipyrine. Dose of products metabolized by hepatic microsomal enzymes to be adjusted when starting or stopping concomitant therapy with ticlopidine hydrochloride.
Theophylline	t1/2 of theophylline increased from 8.6 to 12.2 hr along with a comparable reduction in its total plasma clearance.
Digoxin	Approximately 15% reduction in digoxin plasma levels, (little or no change in digoxin's efficacy expected).
Cimetidine	Chronic administration of cimetidine induced a 50% reduction in clearance of a single dose of ticlopidine hydrochloride.
Antacids	20% decrease in ticlopidine plasma level when administered after antacids.
Phenobarbital	No interaction reported.

Other Concomitant Therapy: Although specific interaction studies were not performed, in clinical studies, TICLID was used concomitantly with beta blockers, calcium channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (however see WARNINGS) without evidence of clinically significant adverse interactions.
ADVERSE REACTIONS Most adverse effects are mild, transient and occur early in the course of treatment.
In controlled clinical trials of 1 to 5 years duration, discontinuation of Ticlid (ticlopidine hydrochloride) due to one or more adverse effects was required in 20.9% of patients. In these same trials, ASA and placebo led to discontinuation in 14.5% and 6.7% of patients respectively. The incidence rates of adverse reactions listed in the following table were derived from multicenter, controlled clinical trials comparing ticlopidine HCl, placebo, and ASA over study periods of up to 5 years. The rates are based on adverse reactions considered probably drug-related by the investigator. Adverse experiences occurring in greater than one percent of patients treated with Ticlid in controlled clinical trials are shown in the Table below.
PERCENT OF PATIENTS IN CONTROLLED STUDIES

	Ticlid (n=2048) Incidence	ASA (n=1527) Incidence	Placebo (n=536) Incidence		Ticlid (n=2048) Incidence	ASA (n=1527) Incidence	Placebo (n=536) Incidence
Event							
Diarrhea	12.5(6.3)*	5.2(1.8)	4.5(1.7)	Nausea	7.0(2.6)	6.2(1.9)	1.7(0.9)
Dyspepsia	7.0(1.1)	9.0(2.0)	0.9(0.2)	Rash	5.1(3.4)	1.5(0.8)	0.6(0.9)
GI Pain	3.7(1.9)	5.6(2.7)	1.3(0.4)	Neutropenia	2.4(1.3)	0.8(0.1)	1.4(0.4)
Purpura	2.2(0.2)	1.6(0.1)	0.0(0.0)	Vomiting	1.9(1.4)	1.4(0.9)	0.9(0.4)
Flatulence	1.5(0.1)	1.4(0.3)	0.0(0.0)	Pruritus	1.3(0.8)	0.3(0.1)	0.0(0.0)
Dizziness	1.1(0.4)	0.5(0.4)	0.0(0.0)	Anorexia	1.0(0.4)	0.5(0.4)	0.0(0.0)

* Percent of patients (in parentheses) discontinuing clinical trials due to event
The incidence of thrombocytopenia in these controlled studies was 0.4% in the Ticlid and placebo groups of patients and 0.3% in the ASA patient population.
The following rare events have been reported and their relationship to Ticlid is uncertain.
Pancytopenia, hemolytic anemia with reticulocytosis, thrombocytopenic thrombotic purpura, jaundice, allergic pneumonitis, systemic lupus (positive ANA), peripheral neuropathy, vasculitis, serum sickness, arthropathy, hepatitis, nephrotic syndrome, myositis, and hyponatremia.
Gastrointestinal: Ticlid therapy has been associated with a variety of gastrointestinal complaints including diarrhea and nausea. The majority of cases are mild and transient in nature and occur within 3 months of initiation of therapy. Typically, events are resolved within 1-2 weeks without discontinuation of therapy. If the effect is severe or persistent, therapy should be discontinued.
Hemorrhagic: Ticlid has been associated with a number of bleeding complications such as ecchymosis, epistaxis, hematuria, conjunctival hemorrhage, gastrointestinal bleeding, and postoperative bleeding.
Intracerebral bleeding was rare in clinical trials with Ticlid, and was no more than that seen with comparator agents (ASA, placebo).
Rash: Ticlopidine hydrochloride has been associated with a maculopapular or urticarial rash (often with pruritus). Rash usually occurs within 3 months of initiation of therapy, with a mean time to onset of 11 days. If drug is discontinued, recovery should occur within several days. Many rashes do not recur on drug rechallenge. There have been rare reports of more severe rashes.
Altered Laboratory Findings: Hematological: Neutropenia and rarely thrombocytopenia have been associated with Ticlid administration (see WARNINGS).
Liver: Ticlid therapy has been associated with elevations of alkaline phosphatase (See WARNINGS). Maximal changes occur within 1-4 months of therapy initiation. No further progressive increases are seen with continuous therapy. Occasionally patients developed deviations in bilirubin and SGOT.
Cholesterol: Chronic Ticlid therapy has been associated with increased serum cholesterol and triglycerides. Serum levels of HDL-C, LDL-C, VLDL-C, and triglycerides are increased 8-10% after 1-4 months of therapy. No further progressive elevations are seen with continuous therapy. The ratios of the lipoprotein subfractions are unchanged. The effect is not correlated with age, sex, alcohol use, or diabetes.
SYMPTOMS AND TREATMENT OF OVERDOSAGE One case of deliberate overdosage with Ticlid (ticlopidine hydrochloride) has been reported in a foreign postmarketing surveillance program. A 38 year old male took a single 6000 mg dose of Ticlid (equivalent to 24 standard 250 mg tablets). The only abnormalities reported were increased bleeding time and increased SGPT. No special therapy was instituted and the patient recovered without sequelae. Based on animal studies, overdosage may result in severe gastrointestinal intolerance.
In the case of excessive bleeding after injury or surgery, standard supportive measures should be carried out if indicated, including gastric lavage, platelet transfusion and use of corticosteroids.
DOSAGE AND ADMINISTRATION The recommended dose of Ticlid (ticlopidine hydrochloride) is 250 mg twice daily with food. Ticlid should be taken with meals to minimize gastrointestinal intolerance.
PHARMACEUTICAL INFORMATION
(i) Drug Substance
Description: Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble in water and self buffers to a pH of 3.6. It also dissolves freely in methanol, is sparingly soluble in buffer solutions above pH 6.0, methylene chloride and ethanol, and is slightly soluble in acetone.
(ii) Composition: Ticlopidine hydrochloride tablets are provided, as white film coated tablets containing ticlopidine hydrochloride, citric acid, povidone, microcrystalline cellulose, corn starch, stearic acid powder, magnesium stearate and water. The coating suspension consists of hydroxypropyl methylcellulose, titanium dioxide and polyethylene glycol. The ink for printing contains D&C yellow #10 aluminum lake and FD&C blue #1 aluminum lake.
(iii) Stability and Storage Recommendations: Store at room temperature. Ticlid tablets should be dispensed in light resistant containers. Blister packs should not be exposed to light.
AVAILABILITY Ticlid 250 mg tablets are oval white film coated tablets printed using green ink with Ticlid above half an arrow on one side, "250" above half an arrow on the other side. The tablets are available in 2-week Patient Starter Packs of 28 tablets (2 blisters of 14 tablets). They are also available in boxes of 56 (4 x 14) tablets and 168 (12 x 14) tablets.
For the first 3 months of therapy, only request or dispense the 14 days supply of tablets (see PRECAUTIONS).
Product Monograph available to Health Professionals on request.
REFERENCES 1. Adapted from Feinberg W. Antithrombotic therapy in stroke and transient ischemic attacks. *American Family Physician* 1989;40(Suppl):53S-9S. 2. Hass WK et al. Ticlopidine Aspirin Stroke Study (TASS). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. *N Eng J Med* 1989;321;501-7. 3. Gent M at al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. *The Lancet* 1989 Jun:1215-20. 4. Ticlopidine Aspirin Stroke Study (TASS). Data on file, Syntex Inc.,Vol.52,Oct 1989. 5. Compendium of Pharmaceuticals and Specialties, 1992. 6. Ticlid product monograph.

See pages iv, v

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

IF YOU'RE LO EFFECTIVE MIGRA YOU'VE JUST S

A recent clinical study published in *The Canadian Journal of Neurological Sciences* makes it clear; Sibelium is very effective in preventing migraine attacks.[1] In fact, the percentage reduction in attack frequency with Sibelium was twice that of propranolol.[1]

In the most common type of migraine, migraine without aura, 73% of patients responded to Sibelium, compared with 44% to propranolol ($p=0.035$).[1] Several studies have also shown Sibelium reduces the severity of migraine and many patients have become attack-free.[2-5]

Sibelium had fewer side effects and was better tolerated than propranolol.[1] There were no unwanted effects on cardiovascular function with Sibelium, whereas propranolol significantly

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

OKING FOR NE PROPHYLAXIS, TRUCK GOLD.

reduced blood pressure and heart rate.[1]
Now you know what you may have already suspected. For patients who...[6]

- suffer 3 or more attacks per month,
- have unusually severe or prolonged attacks, or
- find acute therapy ineffective,

...Sibelium is worth its weight in gold.



once-a-day
℗ SIBELIUM* flunarizine

PREVENTION MAY BE THE BEST CURE.

For brief prescribing information see page xviii

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

THE *Stable* PARKINSON'S PATIENT

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

For brief prescribing information see page xxiv

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

On peut facilement reconnaître le jeune patient épileptique traité au Tegretol® CR.

Excellent contrôle des crises

Tegretol CR (carbamazépine à libération contrôlée) maîtrise les crises chez de nombreux patients, causant peu d'impact sur la fonction cognitive[1,2,3,4]. Contrairement aux médicaments tels la phénytoïne, Tegretol CR permet à de nombreux patients de penser clairement et de donner le meilleur d'eux-mêmes[1,2,3,4].

Taux sanguins uniformes

Tegretol CR cause moins de "hauts et de bas" dans les taux sanguins que le Tegretol conventionnel. Les effets secondaires sont ainsi réduits et le modèle de fonction cognitive est plus stable[5,6].

Posologie b.i.d. commode

Lorsque vous instituez ou remplacez un traitement, pensez au Tegretol CR. Il est présenté en comprimés à 200 mg et 400 mg facilement divisibles pour une plus grande souplesse d'administration et améliorer l'observance du patient.



TEGRETOL® CR.

Aide les épileptiques à réaliser leur plein potentiel.

Geigy Mississauga, Ontario L5N 2W5 PAAB CCPP MEMBRE ACIM G-92111F

For brief prescribing information see pages xx, xxi

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100047296 Published online by Cambridge University Press